With no clear strategy to pursue vaccines or generics like its competitors, and no promising new drugs in the pipeline, Astra Zeneca faces an uncertain future. Acquisitions are costly with a high premium in 2012. Nestle paid about 20 times earnings before interest, depreciation and taxes for Pfizer's baby food nutrition business. Astra Zeneca's first quarter earnings in 2012 declined by 44%. Government price reductions and competition from generics led to first quarter 2012 sales decline by 11%. New management takes over in June from the current CEO.